ClinicalTrials.gg
RecruitingNCT07406217SWISS OPTICOVUpdated Feb 18, 2026

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients

A Phase 2 interventional study of Paxlovid 5 days and Paxlovid 10 days in COVID-19 and Immunodeficiency, sponsored by Calmy Alexandra. Recruiting at 4 sites in Switzerland. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Calmy Alexandra · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 9 months after the study started (first participant enrolled Apr 2023, registered Feb 2026).
  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in COVID-19 with a site in Switzerland — 6 open to participants now, 10 under way, 1 of them phase 3. COVID-19 · Switzerland.

Planned enrollment
17th of 49
256 · median 100
Started
2023
with 6 others
Phase 2
8 of 97
1 open now
Registered
97th of 97
by date
Lead sponsor
2 of 97
Calmy Alexandra

Among the 97 studies in COVID-19 with a site in Switzerland, this one is the 17th largest by planned enrollment of the 49 interventional ones that give a count, is one of 7 that started in 2023, is one of 8 in phase 2, and was the 97th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 97 studies in COVID-19 with a site in Switzerland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in COVID-19 with a site in Switzerland, or all of them as a file.
02

Study summary

The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy direct antiviral agents (remdesivir + nirmatrelvir/r) versus the reference monotherapy (nirmatrelvir/r alone) and to assess the efficacy and safety of increasing the nirmatrelvir/r course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate Coronavirus Disease 2019 (COVID-19).

Read the detailed description

This is a randomized, controlled, factorial, superiority trial to evaluate the viral efficacy of direct antiviral agent nirmatrelvir/r + direct antiviral agent remdesivir versus nirmatrelvir/r alone and of 5 days versus 10 days of nirmatrelvir/r in immunocompromised patients diagnosed with asymptomatic or mild to moderate COVID-19. The primary objective is to assess whether (i) a combination antiviral therapy of two antiviral agents (nirmatrelvir/r + remdesivir and/or (ii) an increase in nirmatrelvir/ r duration from 5 to 10 days improves viral efficacy by decreasing the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV- 2) positivity rate by real time polymerase chain reaction (RT-PCR) (cycle threshold CT\<32) in nasopharyngeal swabs at day 10 (D10). Patients will be eligible if they are immunocompromised, have confirmed asymptomatic SARS-CoV-2 infection or mild to moderate COVID-19, regardless of symptoms onset, provided that they have no contra-indication to any of the study drugs. A total of 256 patients will be recruited in Switzerland and in France, Italy and Norway (through the parallel protocol ANRS0176s OPTICOV).

Participants not eligible for randomisation or who refuse to participate to the trial for any reason will be proposed to be included in an exploratory non comparative cohort (maximum 97 participants, active only in Switzerland).

03

Conditions studied

  • COVID-19
  • Immunodeficiency

Keywords

  • COVID-19
  • Immunodepression
  • SARS-CoV-2
  • Paxlovid
  • Veklury
  • Viral load
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Laboratory confirmed SARS-CoV-2 infection by real time RT-PCR or positive antigenic test (commercialized assay)
  2. Asymptomatic or mild to moderate COVID-19 (WHO progression scale \<5. Patients receiving oxygen therapy for reasons other than a pulmonary COVID-19 are eligible).
  3. ≥ 16 years of age;
  4. as defined by ≥ 1 risk factors for severe COVID-19 as assessed by the Federal Office of Public Health (FOPH) list (criteria 5: diseases/treatments leading to immune suppression) or other immunosuppression criteria such as:

    • Severe immunosuppression (e.g., (HIV) infection with CD4 + T cell count \<350 / μl)
    • Neutropenia (\<1000 neutrophils / μl) ≥1 week
    • Lymphocytopenia (\<200 lymphocytes/μl)
    • On dialysis treatment
    • Hereditary immunodeficiencies
    • Intake of drugs which suppress the immune system (e.g. for a long time [an equivalent dose of prednisone >20 mg/day > 3 months], monoclonal antibodies, cytostatics, biological products, everolimus, mTOR inhibitors etc.) in the last 12 months
    • Active cancer under cytostatics or targeted therapy known to be immunosuppressive (e.g., platinum salts, cyclophosphamide, anthracyclines, taxanes, 5-fluorouracil, gemcitabine, purine inhibitors, proteasome inhibitors) or associated with hematologic toxicity (neutropenia, lymphopenia), for example sunitinib, imatinib, regorafenib.
    • Aggressive lymphomas (all types)
    • Acute lymphatic leukemia
    • Acute myeloid leukemia
    • Acute promyelocytic leukemia
    • T prolymphocytic leukemia
    • Primary central nervous system lymphoma
    • Stem cell transplantation
    • Light chain amyloidosis
    • Chronic lymphoid leukemia
    • Multiple myeloma
    • Sickle cell disease
    • Bone marrow transplant
    • Organ transplant
    • Being on the waiting list for an organ transplant
  5. Willing and able to comply with study requirements and restrictions as described in the form (ICF)
  6. Enrolled in or a beneficiary of a Social Security program (State Medical Aid (AME) is not a Social Security program) or holders of health insurance.
  7. Participant's or its legal representative's signature of the informed consent form

Exclusion criteria

Exclusion Criteria:

  1. SARS-CoV-2 PCR ≥30 CT at screening
  2. to study drugs (active substance(s) or )
  3. Body weight \< 40 kg
  4. (Aspartate transaminase) and/or alanine transaminase (ALT) > 5 times the upper limit
  5. Cirrhosis score C
  6. Is taking or is anticipated to require any prohibited therapies*.
  7. Participation in another interventional clinical study with an compound or device, including COVID-19 therapeutics, where the study intervention is performed in the 28 days preceding the inclusion and the 10 days after the inclusion. Investigators of the different clinical studies should agree on participant's inclusion.
  8. Presence of any condition for which, in the opinion of the investigator, participation would not be in participant's best interest or that could prevent, limit, or confound the protocol-specified assessments
  9. Having received antiviral treatments against SARS-CoV-2 in the 14 days before the inclusion with exception of those having received one or two doses of nirmatrevir/r in the 24h preceding the inclusion in the study.
  10. Pregnant or breastfeeding female
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
256 participants (estimated)

Study arms

  • Other
    Nirmatrelvir/ritonavir (nirmatrelvir/r) 5 days alone

    Nirmatrelvir/r 300mg/100 mg bis in die (twice a day, bid) will be given for 5 days, orally. Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role. Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. Paxlovid® for 5 days is the standard of care.

    Drug: Paxlovid 5 days

  • Experimental
    Nirmatrelvir/ritonavir (nirmatrelvir/r) 10 days alone

    Intervention Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.

    Drug: Paxlovid 10 days

  • Experimental
    Nirmatrelvir/ritonavir (nirmatrelvir/r) 5 days + remdesivir single dose

    Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally. Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role. Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. Remdesivir "flash", 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.

    Drug: Paxlovid 5 days

  • Experimental
    Nirmatrelvir/ritonavir (nirmatrelvir/r) 10 days + remdesivir single dose

    Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally. Remdesivir "flash", 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.

    Drug: Paxlovid 10 days

Interventions

  • DrugPaxlovid 5 days

    Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally. Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role. Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

  • DrugPaxlovid 10 days

    Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.

06

What researchers measure

Primary outcomes

  1. Virological

    Percentage of patients with SARS-CoV-2 viral load \<32 cycle threshold (CT) by real-time RT-PCR in nasopharyngeal swabs at D10 after treatment initiation.

    Time frame: Day 10

Secondary outcomes

  1. Virological

    Percentage of patients with SARS-CoV-2 viral load \<32 CT by real-time RT-PCR in nasopharyngeal swabs at D5, D14 and D21 after treatment initiation

    Time frame: Day 5, Day 14, Day 21

  2. Virological

    Percentage of patients with detectable SARS-CoV-2 viremia at D5, D10 and D14

    Time frame: Day 5, Day 10, Day 14

  3. Virological

    Decrease of SARS-CoV-2 viral load measured by copies/ml by nasopharyngeal swab at D5, D10, D14, D21 and at D5, D10 and D14 in blood samples comparatively to screening

    Time frame: Day 5, Day 10, Day 14, Day 21

  4. Virological

    Number of de novo mutations after sequencing on nasopharyngeal swabs at D5, D10, D14 and D21 comparatively to screening

    Time frame: Day 5, Day 10, Day 14, Day 21

  5. Virological

    To assess the phenotypic resistance (Half maximal inhibitory concentration (IC50) increase) against treatment for viral strains cultured from nasopharyngeal swabs at D5, D10, D14 and D21 comparatively to screening

    Time frame: Day 5, Day 10, Day 14, Day 21

  6. Virological

    Time to first negative SARS-CoV-2 RT-PCR (CT\<32) until D90

    Time frame: Day 90

  7. Virological

    Absence of ability to cultivate virus from viral cultures from nasopharyngeal swabs at D5, D10, D14 and D21

    Time frame: Day 5, Day 10, Day 14, Day 21

  8. Clinical

    Percentage of patients with sustained resolution or abatement of symptoms defined as a inFLUenza Patient-Reported Outcome Plus (FLU-PRO-Plus) score ≤1 at D5, D10, D14, D21 and D28

    Time frame: Day 5, Day 10, Day14, Day 21, Day 28

  9. Clinical

    All-cause hospitalization and/or death at D28

    Time frame: Day 28

  10. Clinical

    Hospitalization at D28

    Time frame: Day 28

  11. Clinical

    Death at D28

    Time frame: Day 28

  12. Clinical

    inFLUenza Patient-Reported Outcome Plus (FLU-PRO-Plus) scale at D5, D10, D14, D21, D28 and D90. Scores range from 0 (symptom free) to 4 (very severe symptoms).

    Time frame: Day 5, Day 10, Day 14, Day 21, Day 28, Day 90

  13. Clinical

    Rate of Post-COVID19 condition at D90 according to the World Health Organisation (WHO) October 2021 definition

    Time frame: Day 90

  14. Clinical

    Percentage of participants with an adverse event (AE) or serious adverse event (SAE) or AE leading to treatment discontinuation up to D90

    Time frame: Day 90

  15. Clinical

    Adherence to nirmatrelvir/r with patient-reported adherence and nirmatrelvir/r residual plasma dosage at D5 and D10, if applicable

    Time frame: Day 5, Day 10

  16. Clinical

    Number of drud-drug interactions who led to dosage adjustment of other patient's drugs

    Time frame: Day 10

  17. Clinical

    Immunosuppressors residual concentrations, if applicable

    Time frame: Day 10

  18. Clinical

    Percentage of patients with specific retreatment (by antiviral, anti-inflammatory drug or convalescent plasma) through D90

    Time frame: Day 90

  19. Clinical

    Number of drug-drug interactions (DDIs) which led to dosage adjustment of other patient's drugs

    Time frame: Day 10

Other outcomes

  1. Treatment discontinuation outcome because of AE or SAE

    Percentage of participants with an adverse event (AE) or serious adverse event (SAE) or AE leading to treatment discontinuation up to D90

    Time frame: Day 90

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual Participant Data are described in the study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Apr 2026, 35 months after the start.

Of 359 non-industry phase 2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 35 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 12, 2026
StartActual
Apr 27, 2023
Primary completionEst.
Apr 10, 2026
CompletionEst.
Jun 30, 2026
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07406217
Lead sponsor
Calmy Alexandra
Responsible party
Calmy Alexandra (Prof, University Hospital, Geneva) — Sponsor-investigator
First posted
Feb 12, 2026
Start date
Apr 27, 2023
Primary completion
Apr 10, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Feb 18, 2026

Study contacts

Alexandra Calmy, MD PhD
Contact
alexandra.calmy@hug.ch
+41 22 372 98 12
Chiara Fedeli, PhD
Contact
chiara.fedeli@hug.ch
+41 (0)22 372 9817
Alexandra Calmy, MD PhD
principal investigator · Hopitaux Universitaires de Genève
Nina Khanna, MD PhD
principal investigator · Basel University Hospital
Nicolas Muller, MD PhD
principal investigator · University of Zurich
Oriol Manuel, MD PhD
principal investigator · University Hospital CHUV

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion